NO20053076L - Farmasoytisk formulering med en uloselig aktiv forbindelse. - Google Patents

Farmasoytisk formulering med en uloselig aktiv forbindelse.

Info

Publication number: NO20053076L
Authority: NO; Norway
Prior art keywords: active compound; pharmaceutical formulation; insoluble active; particulate; less
Prior art date: 2002-12-31

Application number

NO20053076A

Other languages

English (en)

Norwegian (no)

Other versions

NO20053076D0 (no

Inventor

Jeffrey G Weers

Thomas E Tarara

Original Assignee

Nektar Therapeutics

Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)

2002-12-31

Filing date

2005-06-23

Publication date

2005-09-13

Family has litigation

First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=32713146&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=NO20053076(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.

2005-06-23 Application filed by Nektar Therapeutics filed Critical Nektar Therapeutics

2005-06-23 Publication of NO20053076D0 publication Critical patent/NO20053076D0/no

2005-09-13 Publication of NO20053076L publication Critical patent/NO20053076L/no

Links

150000001875 compounds Chemical class 0.000 title abstract 5
239000008194 pharmaceutical composition Substances 0.000 title abstract 4
239000011236 particulate material Substances 0.000 abstract 2
APKFDSVGJQXUKY-KKGHZKTASA-N Amphotericin-B Natural products O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1C=CC=CC=CC=CC=CC=CC=C[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-KKGHZKTASA-N 0.000 abstract 1
APKFDSVGJQXUKY-INPOYWNPSA-N amphotericin B Chemical compound O[C@H]1[C@@H](N)[C@H](O)[C@@H](C)O[C@H]1O[C@H]1/C=C/C=C/C=C/C=C/C=C/C=C/C=C/[C@H](C)[C@@H](O)[C@@H](C)[C@H](C)OC(=O)C[C@H](O)C[C@H](O)CC[C@@H](O)[C@H](O)C[C@H](O)C[C@](O)(C[C@H](O)[C@H]2C(O)=O)O[C@H]2C1 APKFDSVGJQXUKY-INPOYWNPSA-N 0.000 abstract 1
229960003942 amphotericin b Drugs 0.000 abstract 1
150000002632 lipids Chemical class 0.000 abstract 1
210000004072 lung Anatomy 0.000 abstract 1
239000011159 matrix material Substances 0.000 abstract 1
230000002685 pulmonary effect Effects 0.000 abstract 1
XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 abstract 1

Classifications

- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0075—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a dry powder inhaler [DPI], e.g. comprising micronized drug mixed with lactose carrier particles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7048—Compounds having saccharide radicals and heterocyclic rings having oxygen as a ring hetero atom, e.g. leucoglucosan, hesperidin, erythromycin, nystatin, digitoxin or digoxin
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/0078—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy for inhalation via a nebulizer such as a jet nebulizer, ultrasonic nebulizer, e.g. in the form of aqueous drug solutions or dispersions
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/007—Pulmonary tract; Aromatherapy
- A61K9/0073—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy
- A61K9/008—Sprays or powders for inhalation; Aerolised or nebulised preparations generated by other means than thermal energy comprising drug dissolved or suspended in liquid propellant for inhalation via a pressurized metered dose inhaler [MDI]
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/10—Antimycotics
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1611—Inorganic compounds
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1605—Excipients; Inactive ingredients
- A61K9/1617—Organic compounds, e.g. phospholipids, fats
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/16—Agglomerates; Granulates; Microbeadlets ; Microspheres; Pellets; Solid products obtained by spray drying, spray freeze drying, spray congealing,(multiple) emulsion solvent evaporation or extraction
- A61K9/1682—Processes
- A61K9/1694—Processes resulting in granules or microspheres of the matrix type containing more than 5% of excipient

Landscapes

Health & Medical Sciences (AREA)
Engineering & Computer Science (AREA)
Bioinformatics & Cheminformatics (AREA)
Life Sciences & Earth Sciences (AREA)
Chemical & Material Sciences (AREA)
Medicinal Chemistry (AREA)
Pharmacology & Pharmacy (AREA)
Animal Behavior & Ethology (AREA)
General Health & Medical Sciences (AREA)
Public Health (AREA)
Veterinary Medicine (AREA)
Epidemiology (AREA)
Otolaryngology (AREA)
Pulmonology (AREA)
Molecular Biology (AREA)
Dispersion Chemistry (AREA)
Communicable Diseases (AREA)
Oncology (AREA)
Chemical Kinetics & Catalysis (AREA)
General Chemical & Material Sciences (AREA)
Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
Organic Chemistry (AREA)
Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Medicinal Preparation (AREA)

NO20053076A 2002-12-31 2005-06-23 Farmasoytisk formulering med en uloselig aktiv forbindelse. NO20053076L (no)

Applications Claiming Priority (2)

Application Number	Priority Date	Filing Date	Title
US43721002P	2002-12-31	2002-12-31
PCT/US2003/041703 WO2004060351A2 (fr)	2002-12-31	2003-12-31	Formulation pharmaceutique ayant un agent actif insoluble

Publications (2)

Publication Number	Publication Date
NO20053076D0 NO20053076D0 (no)	2005-06-23
NO20053076L true NO20053076L (no)	2005-09-13

Family

ID=32713146

Family Applications (1)

Application Number	Title	Priority Date	Filing Date
NO20053076A NO20053076L (no)	2002-12-31	2005-06-23	Farmasoytisk formulering med en uloselig aktiv forbindelse.

Country Status (18)

Country	Link
US (1)	US20040156792A1 (fr)
EP (1)	EP1589947B2 (fr)
JP (1)	JP2006513236A (fr)
KR (1)	KR20050095838A (fr)
CN (1)	CN1741789A (fr)
AU (1)	AU2003300137A1 (fr)
BR (1)	BR0317810A (fr)
CA (1)	CA2511523C (fr)
EA (1)	EA200501001A1 (fr)
ES (1)	ES2589578T5 (fr)
HU (1)	HUP0500846A3 (fr)
MX (1)	MXPA05007158A (fr)
NO (1)	NO20053076L (fr)
PL (1)	PL378270A1 (fr)
PT (1)	PT1589947T (fr)
TR (1)	TR200502522T2 (fr)
WO (1)	WO2004060351A2 (fr)
ZA (1)	ZA200505155B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US6565885B1 (en) *	1997-09-29	2003-05-20	Inhale Therapeutic Systems, Inc.	Methods of spray drying pharmaceutical compositions
US20060165606A1 (en) *	1997-09-29	2006-07-27	Nektar Therapeutics	Pulmonary delivery particles comprising water insoluble or crystalline active agents
US8404217B2 (en)	2000-05-10	2013-03-26	Novartis Ag	Formulation for pulmonary administration of antifungal agents, and associated methods of manufacture and use
US7871598B1 (en)	2000-05-10	2011-01-18	Novartis Ag	Stable metal ion-lipid powdered pharmaceutical compositions for drug delivery and methods of use
CA2382133C (fr)	2000-05-10	2010-11-23	Alliance Pharmaceutical Corporation	Poudres a base de phospholipides permettant de distribuer un medicament
WO2003053411A1 (fr)	2001-12-19	2003-07-03	Nektar Therapeutics	Administration pulmonaire d'aminoglycosides
TW200503781A (en) *	2002-12-31	2005-02-01	Nektar Therapeutics	Aerosolizable pharmaceutical formulation for fungal infection therapy
MXPA05012821A (es)	2003-05-28	2006-02-13	Nektar Therapeutics	Formulacion farmaceutica que comprende un agente activo insoluble en agua.
US8513204B2 (en) *	2004-06-21	2013-08-20	Novartis Ag	Compositions comprising amphotericin B, mehods and systems
US9061027B2 (en)	2004-08-27	2015-06-23	Board Of Regents, The University Of Texas System	Enhanced delivery of drug compositions to treat life threatening infections
US20090032427A1 (en) *	2005-09-29	2009-02-05	Nektar Therapeutics	Receptacles and Kits, Such as for Dry Powder Packaging
ITMI20051999A1 (it) *	2005-10-21	2007-04-22	Eratech S R L	Formulazioni inalatorie di farmaci in fora di polvere secca per somministrazione come tale o con nebulizzatore e dotate di elevata erogabilita' respirabilita' e stabilita'
US20120128728A1 (en) *	2005-12-28	2012-05-24	Novartis Pharma Ag	Compositions Comprising Amphotericin B
DK1986679T3 (da) *	2006-02-22	2017-11-20	Mannkind Corp	Fremgangsmåde til forbedring af mikropartiklers farmaceutiske egenskaber omfattende diketopiperazin og et aktivt indholdsstof
DE102006053375A1 (de) *	2006-11-10	2008-05-15	Boehringer Ingelheim Pharma Gmbh & Co. Kg	Verfahren zur Mischung von Pulvern
MX2010001311A (es) *	2007-07-31	2010-04-21	Otsuka Pharma Co Ltd	Metodo para producir una suspensi?n de aripiprazol y formulacion liofilizada.
EP2050437A1 (fr) *	2007-10-15	2009-04-22	Laboratoires SMB	Compositions de poudre sèche pharmaceutiquement améliorées pour l'inhalation
PL220269B1 (pl)	2008-04-21	2015-09-30	Przedsiębiorstwo Produkcji Farmaceutycznej Hasco Lek Spółka Akcyjna	Kompozytowy nośnik leków proszkowych, sposób wytwarzania nośnika leków oraz urządzenie do wytwarzania cząstek nośnika kompozytowego
KR101621986B1 (ko)	2008-05-15	2016-05-17	노파르티스 아게	플루오로퀴놀론의 폐 전달
CA2835771C (fr)	2009-03-18	2017-01-24	Incarda Therapeutics, Inc.	Doses unitaires, aerosols, trousses, et methodes pour traiter des affections cardiaques par administration pulmonaire
EP2411137B1 (fr)	2009-03-27	2016-09-07	Bend Research, Inc.	Procédé de séchage par pulvérisation
GB0908129D0 (en) *	2009-05-12	2009-06-24	Innovata Ltd	Composition
TR200904500A2 (tr)	2009-06-10	2009-10-21	Öner Levent	Ezetimib nanokristallerinin hazırlanması için yöntem ve farmasötik formülasyonları.
EP2611530B1 (fr)	2010-09-03	2019-01-16	Bend Research, Inc.	Appareil de séchage par atomisation et procédés d'utilisation de cet appareil
US9084976B2 (en)	2010-09-03	2015-07-21	Bend Research, Inc.	Spray-drying apparatus and methods of using the same
EP2618924A1 (fr)	2010-09-24	2013-07-31	Bend Research, Inc.	Procédé et appareil de séchage par pulvérisation à température élevée
CN103228266B (zh)	2010-10-29	2017-11-14	健康科学西部大学	三元混合物制剂
JOP20120023B1 (ar)	2011-02-04	2022-03-14	Novartis Ag	صياغات مساحيق جافة من جسيمات تحتوي على واحد أو اثنين من المواد الفعالة لعلاج امراض ممرات الهواء الانسدادية او الالتهابية
US20150224202A1 (en) *	2014-02-03	2015-08-13	The Board Of Trustees Of The Leland Stanford Junior University	Formulations and uses for microparticle delivery of zinc protoporphyrins
US11364203B2 (en)	2014-10-31	2022-06-21	Bend Reserch, Inc.	Process for forming active domains dispersed in a matrix
CN104587457B (zh) *	2015-01-13	2017-03-22	广东海大畜牧兽医研究院有限公司	一种利用难溶或不溶蛋白、多肽抗原制备纳米微粒疫苗的方法
SG11201805204WA (en) *	2015-12-24	2018-07-30	Philip Morris Products Sa	Nicotine particle capsule
SG11201805788WA (en)	2016-02-01	2018-08-30	Incarda Therapeutics Inc	Combining electronic monitoring with inhaled pharmacological therapy to manage cardiac arrhythmias including atrial fibrillation
CA3060702A1 (fr)	2017-05-10	2018-11-15	Incarda Therapeutics, Inc.	Doses unitaires, aerosols, trousses, et methodes pour traiter des affections cardiaques par administration pulmonaire
JP2020527377A (ja) *	2017-06-28	2020-09-10	フィリップ・モーリス・プロダクツ・ソシエテ・アノニム	吸入器と併用するための粒子を含む容器
WO2019183470A2 (fr)	2018-03-22	2019-09-26	Incarda Therapeutics, Inc.	Nouvelle méthode pour ralentir le rythme ventriculaire
GB201817860D0 (en)	2018-11-01	2018-12-19	Nicoventures Trading Ltd	Aerosolised formulation
GB201817865D0 (en) *	2018-11-01	2018-12-19	Nicoventures Trading Ltd	Aerosolisable formulation
US11020384B2 (en)	2019-08-01	2021-06-01	Incarda Therapeutics, Inc.	Antiarrhythmic formulation
CA3250825A1 (fr)	2022-03-21	2023-09-28	Cystetic Medicines Inc	Compositions prothétiques à canaux ioniques comprenant des cristaux enrobés de lipides d'amphotéricine b

Family Cites Families (26)

* Cited by examiner, † Cited by third party
Publication number	Priority date	Publication date	Assignee	Title
US437210A (en)		1890-09-30		Electric street-car
SE408265B (sv) *	1975-12-12	1979-06-05	Draco Ab	Anordning for koldioxiddriven endosaerosol, avsedd for inhalering
US4247066A (en) *	1978-02-21	1981-01-27	General Dynamics Corporation	Airfoil variable cambering device and method
IT1116047B (it) *	1979-04-27	1986-02-10	Sigma Tau Ind Farmaceuti	Dispositivo per la rapida inalazione di farmaci in polvere da parte di persone sofferenti di asma
DE3634952A1 (de) *	1986-10-14	1988-04-21	Bayer Ag	Imidazo-pyrrolo-pyridin-derivate
US5049388A (en) *	1986-11-06	1991-09-17	Research Development Foundation	Small particle aerosol liposome and liposome-drug combinations for medical use
CA2112674C (fr) *	1991-07-02	2005-10-04	John S. Patton	Methode et instrument pour la delivrance de medicaments en aerosol
US6582728B1 (en) *	1992-07-08	2003-06-24	Inhale Therapeutic Systems, Inc.	Spray drying of macromolecules to produce inhaleable dry powders
US5785049A (en) *	1994-09-21	1998-07-28	Inhale Therapeutic Systems	Method and apparatus for dispersion of dry powder medicaments
US6051256A (en) *	1994-03-07	2000-04-18	Inhale Therapeutic Systems	Dispersible macromolecule compositions and methods for their preparation and use
JP3388896B2 (ja) *	1994-08-08	2003-03-24	株式会社日立ユニシアオートモティブ	吸入式投薬器
DE4440337A1 (de) *	1994-11-11	1996-05-15	Dds Drug Delivery Services Ges	Pharmazeutische Nanosuspensionen zur Arzneistoffapplikation als Systeme mit erhöhter Sättigungslöslichkeit und Lösungsgeschwindigkeit
ES2237767T3 (es) *	1995-04-14	2005-08-01	Nektar Therapeutics	Composiciones farmaceuticas en polvo que tienen una dispersabilidad mejorada.
US5874064A (en) *	1996-05-24	1999-02-23	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5855913A (en) *	1997-01-16	1999-01-05	Massachusetts Instite Of Technology	Particles incorporating surfactants for pulmonary drug delivery
US6503480B1 (en) *	1997-05-23	2003-01-07	Massachusetts Institute Of Technology	Aerodynamically light particles for pulmonary drug delivery
US5985309A (en) *	1996-05-24	1999-11-16	Massachusetts Institute Of Technology	Preparation of particles for inhalation
WO1998029098A1 (fr) *	1996-12-31	1998-07-09	Inhale Therapeutic Systems, Inc.	Procedes permettant de secher par pulverisation de suspensions aqueuses de medicaments hydrophobes avec des excipients hydrophiles et compositions preparees selon ces procedes
DE69814428T2 (de) *	1997-09-29	2004-05-13	Nektar Therapeutics, San Carlos	In verneblern verwendbare, stabilisierte zubereitungen
US20020017295A1 (en) *	2000-07-07	2002-02-14	Weers Jeffry G.	Phospholipid-based powders for inhalation
US6257233B1 (en) *	1998-06-04	2001-07-10	Inhale Therapeutic Systems	Dry powder dispersing apparatus and methods for their use
WO2000001365A1 (fr) †	1998-06-30	2000-01-13	Leo Pharmaceutical Products Ltd. A/S (Løvens Kemiske Fabrik Produktionsaktieselskab)	Compositions ophtalmiques a liberation prolongee contenant une fluoroquinolone
US20010036481A1 (en) *	1999-08-25	2001-11-01	Advanced Inhalation Research, Inc.	Modulation of release from dry powder formulations
CA2382133C (fr) †	2000-05-10	2010-11-23	Alliance Pharmaceutical Corporation	Poudres a base de phospholipides permettant de distribuer un medicament
US6357490B1 (en) *	2000-08-22	2002-03-19	Advanced Inhalation Research, Inc.	System, method and apparatus for filling containers
WO2002054868A2 (fr) †	2000-12-21	2002-07-18	Inhale Therapeutic Syst	Apport pulmonaire d'agents antifongiques polyene

2003
- 2003-12-31 MX MXPA05007158A patent/MXPA05007158A/es unknown
- 2003-12-31 PL PL378270A patent/PL378270A1/pl unknown
- 2003-12-31 WO PCT/US2003/041703 patent/WO2004060351A2/fr not_active Ceased
- 2003-12-31 ES ES03800395T patent/ES2589578T5/es not_active Expired - Lifetime
- 2003-12-31 BR BR0317810-2A patent/BR0317810A/pt not_active IP Right Cessation
- 2003-12-31 HU HU0500846A patent/HUP0500846A3/hu unknown
- 2003-12-31 PT PT38003950T patent/PT1589947T/pt unknown
- 2003-12-31 EP EP03800395.0A patent/EP1589947B2/fr not_active Expired - Lifetime
- 2003-12-31 US US10/750,934 patent/US20040156792A1/en not_active Abandoned
- 2003-12-31 TR TR2005/02522T patent/TR200502522T2/xx unknown
- 2003-12-31 EA EA200501001A patent/EA200501001A1/ru unknown
- 2003-12-31 KR KR1020057012444A patent/KR20050095838A/ko not_active Withdrawn
- 2003-12-31 JP JP2004564917A patent/JP2006513236A/ja not_active Withdrawn
- 2003-12-31 AU AU2003300137A patent/AU2003300137A1/en not_active Abandoned
- 2003-12-31 CN CNA2003801091328A patent/CN1741789A/zh active Pending
- 2003-12-31 CA CA2511523A patent/CA2511523C/fr not_active Expired - Fee Related
2005
- 2005-06-23 NO NO20053076A patent/NO20053076L/no not_active Application Discontinuation
- 2005-06-24 ZA ZA200505155A patent/ZA200505155B/en unknown

Also Published As

Publication number	Publication date
EP1589947B1 (fr)	2016-06-15
CA2511523C (fr)	2013-10-15
MXPA05007158A (es)	2005-09-21
ES2589578T5 (es)	2019-07-23
US20040156792A1 (en)	2004-08-12
HUP0500846A3 (en)	2008-10-28
EA200501001A1 (ru)	2005-12-29
KR20050095838A (ko)	2005-10-04
JP2006513236A (ja)	2006-04-20
WO2004060351A2 (fr)	2004-07-22
ZA200505155B (en)	2006-04-26
ES2589578T3 (es)	2016-11-15
EP1589947A2 (fr)	2005-11-02
PT1589947T (pt)	2016-09-05
WO2004060351A3 (fr)	2004-09-30
BR0317810A (pt)	2005-11-29
NO20053076D0 (no)	2005-06-23
CA2511523A1 (fr)	2004-07-22
AU2003300137A1 (en)	2004-07-29
PL378270A1 (pl)	2006-03-20
EP1589947B2 (fr)	2019-01-30
EP1589947B8 (fr)	2016-08-24
CN1741789A (zh)	2006-03-01
HUP0500846A2 (en)	2008-05-28
TR200502522T2 (tr)	2005-09-21

Publication	Publication Date	Title
NO20053076L (no)	2005-09-13	Farmasoytisk formulering med en uloselig aktiv forbindelse.
WO2008019996A3 (fr)	2008-09-04	Formulations de flibansérine et leur procédé de fabrication
WO2006102446A3 (fr)	2006-12-21	Composition multiparticulaire a liberation modifiee
AR018143A1 (es)	2001-10-31	Formulacion para preparar un comprimido de desintegracion rapida, comprimidos de desintegracion rapida, especialmente comprimidos de desintegracionrapida en la boca
NO20076613L (no)	2008-03-03	Farmasoytiske formuleringer og anvendelse derav
DE69838300D1 (de)	2007-10-04	Pharmazeutische suspensionstabletten-zusammenstellungen
NO20081889L (no)	2008-04-21	Fast vaksine formulering
NO20082988L (no)	2008-08-29	Vedvarende frigivningsformulering innbefattende oktreotid og to eller flere polylaktid-ko-glykolidpolymerer
ATE541562T1 (de)	2012-02-15	Ibuprofen-suspension
UA90518C2 (ru)	2010-05-11	Фармацевтическая композиция в форме таблетки, которая имеет улучшеное всасывание при трансбукальном введение, которая содержит наркотический активный ингредиент и амин
AR034517A1 (es)	2004-02-25	Formulacion farmaceutica
ITMI20022292A1 (it)	2004-04-30	9a-azalidi ad attivita' antiinfiammatoria.
TNSN97134A1 (fr)	2005-03-15	Comprime de maleate de trimebutine pellicule
MXPA03005221A (es)	2004-03-26	Composicion farmaceutica de dronedarona para administracion parenteral.
DE60102590D1 (de)	2004-05-06	Darreichungsformen zur behandlung von oralen mykosen
NO20076108L (no)	2008-02-15	Gelatin-inneholdende topikal sammensetning
HRP20050342B1 (hr)	2013-11-08	Farmaceutska formulacija olanzapina
WO2007144902A8 (fr)	2008-12-31	Formulation sous forme de comprimé à mâcher bicouche
IL200447A0 (en)	2011-07-31	Compressed solid dosage form manufacturing process well-suited for use with drugs of low aqueous solubility and compressed solid dosage forms made thereby
NO20054417L (no)	2005-09-23	Fremgangsmate for fremstilling av farmasoytiske preperater i form av fibratholdige tabletter og de derved fremstilte tabletter
WO2006033505A8 (fr)	2006-09-14	Sels derives de cholate de paroxetine ou d'acide cholique, et composition comportant de la paroxetine et de l'acide cholique ou des derives de l'acide cholique
WO2005023223A3 (fr)	2005-05-26	Forme galenique a administration orale pour substances actives acides et amphoteres difficilement solubles
JP2004002473A5 (fr)	2005-08-25
WO1999066902A8 (fr)	2001-02-15	Formulations pharmaceutiques injectables de derives de la partricine
GB0006897D0 (en)	2000-05-10	Medicaments

Legal Events

Date	Code	Title	Description
2008-07-21	FC2A	Withdrawal, rejection or dismissal of laid open patent application